Compile Data Set for Download or QSAR
Report error Found 65 Enz. Inhib. hit(s) with all data for entry = 10724
TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562168(US11401256, Example 60 | 6-(3,4-Dihydro-2H-quinoli...)
Affinity DataKd:  1nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562157(US11401256, Example 49 | N-Methyl-2-[3-(methylcarb...)
Affinity DataKd:  2nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562167(US11401256, Example 59 | 6-(2,3-Dihydropyrrolo[2,3...)
Affinity DataKd:  3nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562132(US11401256, Example 25 | 2-(4-Methoxypyridin-2-yl)...)
Affinity DataKd:  3nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562149(US11401256, Example 42 | 2-(3-Acetamido-2-pyridyl)...)
Affinity DataKd:  4nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562138(US11401256, Example 31 | N-Methyl-2-[2-(methylcarb...)
Affinity DataKd:  4nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562156(US11401256, Example 48 | 2-(2-Acetyl-3-pyridyl)-N-...)
Affinity DataKd:  4nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562125(US11401256, Example 18 | 2-(2-Aminoethyl)-N-methyl...)
Affinity DataKd:  4nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562128(US11401256, Example 21 | (RS)—N-(7-Oxo-5,6,7,...)
Affinity DataKd:  4nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562129(US11401256, Example 22 | Methyl 2-(2-methoxypyridi...)
Affinity DataKd:  4nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562164(US11401256, Example 56 | 6-(3,4-Dihydro-2H-quinoli...)
Affinity DataKd:  5nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562146(US11401256, Example 39 | 2-(4-Methoxy-6-methyl-2-p...)
Affinity DataKd:  6nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562145(US11401256, Example 38 | 2-(2-Aminophenyl)-N-methy...)
Affinity DataKd:  6nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562135(US11401256, Example 28 | 2-Isopropyl-N-methyl-1-(7...)
Affinity DataKd:  8nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562121(US11401256, Example 14 | 6-(5-Phenyl-1H-imidazol-1...)
Affinity DataKd:  9nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562151(US11401256, Example 44 | 2-(5-Fluoro-2-methoxy-4-p...)
Affinity DataKd:  10nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562117(US11401256, Example 10 | 2-(2-Methoxybenzyl)-N-met...)
Affinity DataKd:  10nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562127(US11401256, Example 20 | N-Methyl-2-(morpholine-4-...)
Affinity DataKd:  10nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562124(US11401256, Example 17 | Ethyl 5-(methylcarbamoyl)...)
Affinity DataKd:  10nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562122(US11401256, Example 15 | 2-(Hydroxymethyl)-N-methy...)
Affinity DataKd:  11nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562159(US11401256, Example 51 | 2-Isopropyl-N-methyl-1-(6...)
Affinity DataKd:  11nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562131(US11401256, Example 24 | 2-(6-Methoxypyridin-3-yl)...)
Affinity DataKd:  12nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562153(US11401256, Example 46 | 2-[2-(Hydroxymethyl)-4-py...)
Affinity DataKd:  14nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562142(US11401256, Example 35 | 2-(2-Fluoro-5-methoxy-phe...)
Affinity DataKd:  14nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562133(US11401256, Example 26 | 2-(2-Methoxypyridin-3-yl)...)
Affinity DataKd:  15nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562130(US11401256, Example 23 | 2-(6-Methoxypyridin-2-yl)...)
Affinity DataKd:  15nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562116(US11401256, Example 9 | 6-(1H-Imidazol-1-yl)-3,4-d...)
Affinity DataKd:  16nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562161(US11401256, Example 53 | 7-(1H-Imidazol-1-yl)-3,4-...)
Affinity DataKd:  16nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562155(US11401256, Example 47 | 2-[[2-Methoxy-4-(trifluor...)
Affinity DataKd:  17nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562139(US11401256, Example 32 | 2-(3-Methoxyphenyl)-N-met...)
Affinity DataKd:  17nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562158(US11401256, Example 50 | Methyl 2-isopropyl-1-(6-o...)
Affinity DataKd:  20nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562134(US11401256, Example 27 | 6-(5-(4-Methoxyphenyl)-1H...)
Affinity DataKd:  22nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562160(US11401256, Example 52 | 2-Isopropyl-N,N-dimethyl-...)
Affinity DataKd:  22nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562163(US11401256, Example 55 | 6-(2,3-Dihydropyrrolo[2,3...)
Affinity DataKd:  23nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562123(US11401256, Example 16 | 2-(2-(Cyclopropanecarboxa...)
Affinity DataKd:  27nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562152(US11401256, Example 45 | N-Methyl-1-(2-oxo-3,4-dih...)
Affinity DataKd:  27nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562126(US11401256, Example 19 | Methyl 4-((2-oxo-1,2,3,4-...)
Affinity DataKd:  30nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562150(US11401256, Example 43 | 2-(3-Amino-2-pyridyl)-N-m...)
Affinity DataKd:  31nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562120(US11401256, Example 13 | 2-(2-Methoxypyridin-4-yl)...)
Affinity DataKd:  31nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562136(US11401256, Example 29 | 2-(2-Methoxy-4-pyridyl)-N...)
Affinity DataKd:  35nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562143(US11401256, Example 36 | 2-[2-(Hydroxymethyl)pheny...)
Affinity DataKd:  39nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562109(US11401256, Example 2 | N-Methyl-2-[2-(3-methylimi...)
Affinity DataKd:  40nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562165(US11401256, Example 57 | N-(1-Acetyl-4-piperidyl)-...)
Affinity DataKd:  41nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562139(US11401256, Example 32 | 2-(3-Methoxyphenyl)-N-met...)
Affinity DataKd:  45nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562111(US11401256, Example 4 | N-Methyl-1-(2-oxo-1,2,3,4-...)
Affinity DataKd:  49nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562166(US11401256, Example 58 | 6-(Indoline-1-carbonyl)-3...)
Affinity DataKd:  62nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562148(US11401256, Example 41 | Methyl 2-[[5-(methylcarba...)
Affinity DataKd:  68nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562147(US11401256, Example 40 | Methyl 2-[5-(methylcarbam...)
Affinity DataKd:  69nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562170(US11401256, Example 62 | 2-Isopropyl-N-methyl-1-(2...)
Affinity DataKd:  120nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetProtein cereblon(Human)
C4 Therapeutics

US Patent
LigandPNGBDBM562169(US11401256, Example 61 | 6-(2-Isopropyl-1H-benzo[d...)
Affinity DataKd:  171nMAssay Description:Process 1) Optimization of measurement parameters to minimize protein consumption and to minimize the dilution effect and the DMSO content 2) Titrati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

Displayed 1 to 50 (of 65 total ) | Next | Last >>
Jump to: